| アブストラクト | Purpose: This real-world data study evaluates demographic and clinical characteristics and survival in patients with liposarcoma to inform our understanding of treatment patterns and associated outcomes in this rare cancer. Materials and methods: A retrospective cohort study was conducted using existing data available through the Clinical Practice Research Datalink. Male and female patients aged 18 years or older who had their first ever record of liposarcoma between 1998 and 2018 were included in the study. The demographic and tumour characteristics were presented (overall, by first line treatment and for dedifferentiated liposarcoma only) as proportions (percentages) while continuous variables were presented as means with standard deviation and interquartile ranges. Survival rates from diagnosis date and first line treatment (with 95% confidence intervals) were also calculated. Results: 1,315 patients were included, of which 46% (611) had a treatment recorded. Most patients were male and over the age of 60 years. Surgery was the most frequent treatment received following diagnosis (34% of all patients), followed by radiotherapy (8%) and chemotherapy (2.4%) with the remaining patients having no record of treatment available. Overall, there was a 77% probability of survival after diagnosis at 5 years. Conclusions: Findings from this study help advance our understanding of real world patient characteristics, treatment patterns and survival outcomes in a rare and heterogeneous cancer, which may be useful for guiding clinical management. This study also identified challenges with using real world data, which can be minimised through improving data collection and standardisation. |
|---|
| ジャーナル名 | Rare tumors |
|---|
| Pubmed追加日 | 2025/7/30 |
|---|
| 投稿者 | Oyinlola, Jessie O; Beloueche-Babari, Mounia; Frysz, Monika; Yelland, Eleanor; Walker, Amy; Williams, Rachael; Jones, Robin L |
|---|
| 組織名 | Clinical Practice Research Datalink (CPRD), Safety and Surveillance Group,;Medicines and Healthcare Products Regulatory Agency, London, UK. RINGGOLD: 9059;Boehringer Ingelheim Ltd, Bracknell, UK. RINGGOLD: 33428;The Royal Marsden Hospital and Institute of Cancer Research, London, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40735628/ |
|---|
